John Lambris, PhD, and Daniel Ricklin, PhD, are co-authors of a recent study describing a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. The research team outlines a strategy based on the complement system, the oldest part of the human immune system, that could turn out to be less costly and more effective for the majority of patients with the rare but life-threatening hematological disorder paroxysmal nocturnal hemoglobinuria (PNH). The study "Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria" was published this month in Blood.

Read the Department of Communications news release.